Jan 23, 2019 - Aurinia Pharmaceuticals' voclosporin ophthalmic solution comes in line with safety in head to head study with Restasis for dry eye disease but beats it on two efficacy secondary endpoints.Voclosporin
Jan 22, 2019 -
Jan 21, 2019 - Bernard Horn's Polaris Global Value Fund 4th Quarter Commentary, Stocks: ABCB,MEOH,LXS,AGN,TEVA,, Bernard Horn, release date:Jan 21, 2019
Jan 16, 2019 - Ironwood Pharmaceuticals (IRWD) gets approval for Linzess in China for the treatment of adults with IBS-C
Jan 15, 2019 - Aurinia Pharmaceuticals is expected to release results from its phase 2 dry eye disease study any day now in January of 2019.The global dry eye disease market is expected to reach $7.7 billion by 2025
Jan 11, 2019 - Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.
Jan 07, 2019 - Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.
Jan 04, 2019 - Merck takes option to license NGM313 drug for NASH, which will be used in a phase 2 study known under a different name as MRK-3655.The main deal between Merck & NGM Bio was $450 million to develop bio
Jan 04, 2019 - Allergan (AGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Dec 19, 2018 - Synergy filed for bankruptcy after failing to amend the liquidity and revenue covenants of its loan facility with private lender CRG.Bausch Health has offered $200 million for its assets; other bids m